A GROUNDBREAKING TOOL FOR TYPE 1 DIABETES TREATMENT R&D.
The T1DMS is a computer simulator of the human metabolic system based on the Meal Model of glucose-insulin dynamics. In January 2008, T1DMS became the first computer tool accepted by the FDA as a substitute for animal trials in the pre-clinical testing of certain control strategies in T1DM. TEG offers services for the development and optimization of T1D-related devices, protocols, and treatments using the T1D metabolic simulator along with the full FDA-accepted in silico patient population. Additionally, TEG distributes and supports a Distributed Version of the T1D metabolic simulator (with a smaller “sample” in silico patient population) to simplify access for the wider diabetes research community. T1DMS can be used to (i) test the safety and effectiveness of new therapies under varying conditions, (ii) compare existing treatments, and (iii) bolster R&D and product strategies.
The Continuous Glucose-Error Grid Analysis (CG-EGA) is a Windows-based, statistical program designed for use by the diabetes technology industry in the evaluation of continuous glucose monitoring devices. It is a logical extension of the original error grid analysis (EGA), which was developed for assessing the clinical accuracy of patient-determined blood glucose values using either estimation or self-monitoring blood glucose systems. CG-EGA is based upon the premise that information being generated by a monitoring system should be reliable enough to result in clinically accurate decision making by the user.